The 2024 Clinical Practice Guideline for the Management of Lupus Nephritis is a focused update of the lupus nephritis (LN) chapter of The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The Lupus Nephritis Guideline was published in the January 2024 issue of Supplements to Kidney International, with an Executive Summary published in the main pages of the journal. The guideline was co-chaired by Brad Rovin, MD (United States) and Jürgen Floege, MD (Germany), who co-chaired the 2021 Glomerular Diseases Guideline and will co-chair future chapter updates.
Drawing from the latest approvals of belimumab and voclosporin by the FDA and EMA, the guideline provides updated recommendations and practice points for using these new therapies as add-on immunosuppressive agents in the management of LN. The development of the guideline followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations were based on systematic reviews of relevant studies. Appraisal of the quality of the evidence and the strength of recommendations followed the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) approach. Graded recommendations are categorized by strength and certainty of evidence, while practice points serve as expert guidance to complement these recommendations. Limitations of the evidence are discussed, with areas for future research also presented. As part of KDIGO’s transparent guideline development process, the draft guideline was made available for public comment in March 2023, receiving valuable feedback, which was meticulously reviewed and considered by the Guideline Work Group.
Please visit the KDIGO Glomerular Diseases Guideline website for more resources.
KDIGO 2024 Lupus Nephritis Guideline Top 10 Takeaways - Russian
Ключевые положения Клинических Практических Рекомендаций KDIGO 2024 по ведению волчаночного нефрита
DISCLAIMER: USE OF THE CLINICAL PRACTICE GUIDELINES
This Clinical Practice Guideline is based upon the best information available at the time of publication. The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of this Guideline is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.
